Wednesday, September 28, 2022 8:56:18 AM
Investors participating in bioAffinity Technologies’ financing exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and 310,910 non-tradable warrants at a price of $7.656 per share. Combined with the Company's underwritten public offering of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant and one non-tradeable warrant, in which the Company announced the receipt of gross proceeds of approximately $7.9 million, the Company has received an aggregate of approximately $15.6 million as of September 28, 2022.
The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath® Lung, a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a person’s sputum, or phlegm. The test’s automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. CyPath® Lung has the potential to increase overall diagnostic accuracy of lung cancer diagnosis leading to increased survival while lowering the number of unnecessary invasive procedures, reducing patient anxiety, and lowering medical costs.
Proceeds may also be used in the Company’s pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes.
Recent BIAF News
- bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes • Business Wire • 05/15/2024 01:15:00 PM
- bioAffinity Technologies News Update • Business Wire • 05/02/2024 12:00:00 PM
- bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth • Business Wire • 04/24/2024 12:00:00 PM
- bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening • Business Wire • 04/09/2024 12:00:00 PM
- bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 04/01/2024 01:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:45 PM
- Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 03/08/2024 06:15:00 PM
- bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement • Business Wire • 03/08/2024 05:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 05:18:40 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 02:57:51 AM
- WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 03/06/2024 03:45:00 PM
- bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement • Business Wire • 03/06/2024 02:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:26:46 PM
- bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung • Business Wire • 03/05/2024 01:00:00 PM
- bioAffinity Technologies News Update • Business Wire • 02/21/2024 01:00:00 PM
- Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice • Business Wire • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:22:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:21:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:17:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:05:25 PM
- bioAffinity Technologies In The News • Business Wire • 01/30/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:34 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM